Anthony MBA - Virpax Pharmaceuticals Chairman CEO
| VRPX Stock | USD 0.46 0.02 4.17% |
Insider
Anthony MBA is Chairman CEO of Virpax Pharmaceuticals
| Age | 62 |
| Address | 1055 Westlakes Drive, Berwyn, PA, United States, 19312 |
| Phone | 610-727-4597 |
| Web | https://www.virpaxpharma.com |
Virpax Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.9142) % which means that it has lost $0.9142 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6229) %, meaning that it created substantial loss on money invested by shareholders. Virpax Pharmaceuticals' management efficiency ratios could be used to measure how well Virpax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.66 in 2024. Return On Capital Employed is likely to rise to -7.71 in 2024. At this time, Virpax Pharmaceuticals' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 45.3 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 313.9 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Tiago Marques | Pasithea Therapeutics Corp | 47 | |
| Chester III | Revelation Biosciences | 44 | |
| Yassine Bendiabdallah | Pasithea Therapeutics Corp | 40 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Dr B | Praxis Precision Medicines | N/A | |
| Carol Odle | Revelation Biosciences | N/A | |
| Karl Hansen | Praxis Precision Medicines | N/A | |
| Jason Davis | Virax Biolabs Group | 52 | |
| MD BA | Pasithea Therapeutics Corp | 76 | |
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| Daniel Schneiderman | Pasithea Therapeutics Corp | 46 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Jeffrey PharmD | Nutriband | 54 | |
| Timothy Kelly | Praxis Precision Medicines | 51 | |
| Lauren Mastrocola | Praxis Precision Medicines | N/A | |
| James Foster | Virax Biolabs Group | 39 | |
| MD FACC | Longeveron LLC | 61 | |
| James Rolke | Revelation Biosciences | 55 | |
| MaryJane Rafii | Kiora Pharmaceuticals | N/A | |
| Tomasz George | Virax Biolabs Group | 40 | |
Management Performance
| Return On Equity | -3.62 | ||||
| Return On Asset | -0.91 |
Virpax Pharmaceuticals Leadership Team
Elected by the shareholders, the Virpax Pharmaceuticals' board of directors comprises two types of representatives: Virpax Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Virpax. The board's role is to monitor Virpax Pharmaceuticals' management team and ensure that shareholders' interests are well served. Virpax Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Virpax Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO Sec | ||
| Jeffrey MD, Chief VP | ||
| JD MBA, Chief Officer | ||
| MBA ACA, Principal CFO | ||
| Shana Panzarella, Chief Staff | ||
| Anthony MBA, Chairman CEO | ||
| Jatinder Dhaliwal, CEO Director | ||
| Gerald Bruce, CEO Director |
Virpax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Virpax Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.62 | ||||
| Return On Asset | -0.91 | ||||
| Current Valuation | 3.71 M | ||||
| Shares Outstanding | 4.89 M | ||||
| Shares Owned By Insiders | 2.57 % | ||||
| Shares Owned By Institutions | 0.03 % | ||||
| Number Of Shares Shorted | 315.03 K | ||||
| Price To Book | 0.48 X | ||||
| EBITDA | (2.25 M) | ||||
| Net Income | (15.19 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virpax Stock Analysis
When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.